FRESENIUS SE & CO. KGAA (FRA:FRE) Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21

Transparency directive : regulatory news

01/02/2021 22:49

DGAP-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Forecast
Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21

01-Feb-2021 / 22:49 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21

Current Group expectations for FY/21
Based on the current status of the Group's financial planning process and assuming that the current burdens and constraints caused by the COVID-19 pandemic only begin to recede in the second half of the year, Fresenius targets healthy sales growth¹ and at least broadly stable net income² year over year in FY/21. The FY/21 earnings are, hence, expected to be very meaningfully impacted by COVID-19 effects. In particular, as reported today by Fresenius Medical Care, the significant acceleration of mortality among dialysis patients due to COVID-19 is expected to have a material impact on Fresenius Medical Care's results and hence on Fresenius Group's net income² growth.

Group medium-term targets
The current information and assumptions do not trigger a revision of Fresenius' medium-term growth targets, which were set before the COVID-19 pandemic emerged.

Fresenius will announce more detailed FY/21 financial guidance with the release of its FY/20 results on February 23, 2021.

¹ in constant currency
² Net income attributable to shareholders of Fresenius SE & Co. KGaA; in constant currency; before any special items and any one-time expenses related to likely efficiency and cost saving programs

For additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures.

Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
The Management Board

Bad Homburg v.d.H., February 1, 2021

----------------------------------------
Contact:
Markus Georgi
Senior Vice President Investor Relations & Sustainability
T: +49 (0) 6172 608-2485
markus.georgi@fresenius.com
----------------------------------------

End of Note

01-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Fresenius SE & Co. KGaA
	Else-Kröner-Straße 1
	61352 Bad Homburg v.d.H.
	Germany
Phone:	+49 (0)6172 608-2485
Fax:	+49 (0)6172 608-2488
E-mail:	ir-fre@fresenius.com
Internet:	www.fresenius.com
ISIN:	DE0005785604
WKN:	578560
Indices:	DAX
Listed:	Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange
EQS News ID:	1164992


End of Announcement	DGAP News Service

1164992 01-Feb-2021 CET/CEST

FRESENIUS SE & CO. KGAA's latest news

05/12/2023 21:29

FRESENIUS SE & CO. KGAA (FRA:FRE) Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21

Transparency directive : regulatory news

FRESENIUS SE & CO. KGAA's latest news

Other stories